Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer

被引:8
|
作者
Nicos, Marcin [1 ]
Krawczyk, Pawel [1 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, PL-20954 Lublin, Poland
关键词
NSCLC; tumor evolution; driver mutations; clonal; subclonal alterations; metastases; STEM-CELLS; INTRATUMOR HETEROGENEITY; MESENCHYMAL TRANSITION; TUMOR EVOLUTION; BRANCHED EVOLUTION; BRAIN METASTASES; T790M MUTATION; CD133(+) CELLS; ADENOCARCINOMA; NOTCH;
D O I
10.3390/cancers14071813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Limited knowledge about NSCLC evolution has affected therapeutic strategies for many decades. The application of NGS-based techniques to studies on ITH has provided genetic insight into the contribution of clonality primary seeding, as well as to distant dissemination. To date, multiregional ITH affects accurate diagnosis and treatment decisions and is considered the main hallmark of anticancer therapy failure. Understanding the evolutionary trajectories that drive the metastatic process is critical for improving treatment strategies for this deadly condition. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC, highlighting that wide genetic analyses may reveal the phylogenetic lineages of NSCLC evolution. Data indicate that many driver alterations from the primary tumor of non-small cell lung cancer (NSCLC) are predominantly shared across all metastases; however, disseminating cells may also acquire a new genetic landscape across their journey. By comparing the constituent subclonal mutations between pairs of primary and metastatic samples, it is possible to derive the ancestral relationships between tumor clones, rather than between tumor samples. Current treatment strategies mostly rely on the theory that metastases are genetically similar to the primary lesions from which they arise. However, intratumor heterogeneity (ITH) affects accurate diagnosis and treatment decisions and it is considered the main hallmark of anticancer therapy failure. Understanding the genetic changes that drive the metastatic process is critical for improving the treatment strategies of this deadly condition. Application of next generation sequencing (NGS) techniques has already created knowledge about tumorigenesis and cancer evolution; however, further NGS implementation may also allow to reconstruct phylogenetic clonal lineages and clonal expansion. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC. We highlight that wide genetic analyses may reveal the phylogenetic trajectories of NSCLC evolution, and may pave the way to better management of follow-up and treatment.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Surgical management of oligometastatic non-small cell lung cancer
    Novoa, Nuria M.
    Varela, Gonzalo
    Jimenez, Marcelo F.
    JOURNAL OF THORACIC DISEASE, 2016, 8 : S895 - S900
  • [32] Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
    Sampsonas, Fotios
    Bosgana, Pinelopi
    Bravou, Vasiliki
    Tzouvelekis, Argyrios
    Dimitrakopoulos, Foteinos-Ioannis
    Kokkotou, Eleni
    GENES, 2024, 15 (07)
  • [33] Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua
    Chen, Xianguo
    Xu, Bo
    Li, Qiang
    Xu, Xiaoyi
    Li, Xianshuai
    You, Xia
    Yu, Zhaonan
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (09):
  • [34] Association of Mutation Profiles with Postoperative Survival in Patients with Non-Small Cell Lung Cancer
    Goto, Taichiro
    Kunimasa, Kei
    Hirotsu, Yosuke
    Nakagomi, Takahiro
    Yokoyama, Yujiro
    Higuchi, Rumi
    Otake, Sotaro
    Oyama, Toshio
    Amemiya, Kenji
    Mochizuki, Hitoshi
    Omata, Masao
    CANCERS, 2020, 12 (11) : 1 - 16
  • [35] To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
    Cai, Ruoxue
    Zhu, Hongyu
    Liu, Ying
    Sha, Huanhuan
    Peng, Weiwei
    Yin, Rong
    Zhou, Guoren
    Fang, Ying
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10027 - 10040
  • [36] Partial transformation from non-small cell lung cancer to small cell lung cancer: a case report and literatures review
    Lu, Yicong
    Fang, Danruo
    Guo, Jiangying
    Huang, Huaqiong
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [37] Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer
    Saigi, M.
    McLeer-Florin, A.
    Pros, E.
    Nadal, E.
    Brambilla, E.
    Sanchez-Cespedes, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (07) : 881 - 888
  • [38] Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
    Fois, Sara S.
    Paliogiannis, Panagiotis
    Zinellu, Angelo
    Fois, Alessandro G.
    Cossu, Antonio
    Palmieri, Giuseppe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) : 1 - 19
  • [39] Notch signaling and targeted therapy in non-small cell lung cancer
    Sun, Jiajun
    Dong, Meichen
    Xiang, Xin
    Zhang, Shubing
    Wen, Doudou
    CANCER LETTERS, 2024, 585
  • [40] EGFR TKI combination with immunotherapy in non-small cell lung cancer
    Ahn, Myung-Ju
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 465 - 469